Daniel J. George, MD, Duke Cancer Institute
Articles
Emerging Therapies for Advanced Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Genetic Testing in Metastatic CRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Impact of Clinical Data on the Treatment of mCRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
The CARD and PROfound Trials for Metastatic CRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Differences Between AR-Targeted Therapy in Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Overall Survival Data Presented at ASCO 2020 for nmCRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
FDA Approved Agents for Non-Metastatic CRPC
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Clinical Trials in the Community Setting for Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Data for Metastatic Castration-Sensitive Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Conventional Versus PSMA Imaging in Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
PSMA-Targeted Imaging in Prostate Cancer
Daniel J. George, MD, Duke Cancer Institute;Tanya Dorff, MD, City of Hope Comprehensive Cancer Center;Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center;Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology;Charles Ryan, MD, University of Minnesota
July 9th 2020Read More
Latest Updated Articles
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
